ADCETRIS Shows Promising Results in PTCL Patients at ASCO

Seagen's CD30-directed antibody-drug conjugate, ADCETRIS (brentuximab vedotin), has shown encouraging results from the Phase II SGN35-032 study in patients with peripheral T-cell lymphoma (PTCL) exhibiting less than 10% CD30 expression. The findings were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024.

The study enrolled 82 patients and evaluated the efficacy and safety of ADCETRIS in combination with cyclophosphamide, doxorubicin, and prednisone (A+CHP) as a first-line treatment for patients with non-systemic anaplastic large cell lymphoma (sALCL) PTCL that expresses CD30 at levels below 10%. As of the data cutoff on January 31, 2024, 45 patients remained in follow-up, with a median follow-up duration of 11.65 months.

Key efficacy outcomes indicated that among 74 response-evaluable patients, the overall response rate (ORR) was 80%. The complete response (CR) rate stood at 64% based on subgroup analyses.

Safety data revealed no new safety signals, and adverse events were consistent with the known safety profile of A+CHP. Grade 3 or higher treatment-emergent adverse events (TEAEs) were experienced by 46 patients, and six patients discontinued treatment due to TEAEs. Two treatment-related deaths were reported.

PTCL is a heterogeneous and aggressive group of lymphomas with generally poor prognoses. While CD30 expression varies among PTCL subtypes, it is an important marker in certain forms. The study results suggest that ADCETRIS may offer a new treatment avenue for PTCL patients with previously limited options, particularly those with low CD30 expression.